Tech Company Financing Transactions

Ceptaris Therapeutics Funding Round

On 11/26/2007, Ceptaris Therapeutics landed $14.5 million in Series C financing from Vivo Capital, Palo Alto Investors and private investors.

Transaction Overview

Announced On
Transaction Type
Venture Equity
Series C

Vivo Capital (Lead Investor) (Albert Cha)

Palo Alto Investors

Proceeds Purpose
The financing will support the ongoing clinical development program for Clearazide(TM), a topically delivered cytotoxic agent for the treatment of cutaneous T-cell lymphoma (CTCL) that is currently in pivotal clinical studies. The funding will also position Yaupon to pursue neuropsychiatric indications such as Attention Deficit Disorder (ADD) and Tourette's syndrome for Lobeline, a dopamine modulating agent that is currently in phase 2 trials for methamphetamine addiction. The funding will also help to bring Yaupon's pain programs into clinical stage development.

Company Information

Company Status
Acquired or Merged
Mailing Address
101 Lindenwood Dr. 400
Malvern, PA 19355
Email Address
Ceptaris Therapeutics Inc., a privately held, specialty pharmaceutical company, is developing a proprietary formulation of mechlorethamine gel for the treatment of early stage (stages I-IIA) mycosis fungoides, a type of Cutaneous T-Cell Lymphoma.
Ceptaris Therapeutics LinkedIn Company Profile
Social Media
Ceptaris Therapeutics Company Twitter Account
Company News
Ceptaris Therapeutics News
Ceptaris Therapeutics on Facebook
Ceptaris Therapeutics on YouTube

Management Team

Email & Social
Chief Executive Officer
Steve Tullman
  Steve Tullman LinkedIn Profile  Steve Tullman Twitter Account  Steve Tullman News  Steve Tullman on Facebook
Chief Medical Officer
Jeffrey Wilkins
  Jeffrey Wilkins LinkedIn Profile  Jeffrey Wilkins Twitter Account  Jeffrey Wilkins News  Jeffrey Wilkins on Facebook
Chief Operating Officer
Douglas Gssl
  Douglas Gssl LinkedIn Profile  Douglas Gssl Twitter Account  Douglas Gssl News  Douglas Gssl on Facebook
VP - Bus. Development
Evan Dick
  Evan Dick LinkedIn Profile  Evan Dick Twitter Account  Evan Dick News  Evan Dick on Facebook
VP - General Counsel
Kamil Ali-Jackson
  Kamil Ali-Jackson LinkedIn Profile  Kamil Ali-Jackson Twitter Account  Kamil Ali-Jackson News  Kamil Ali-Jackson on Facebook
VP - Operations
Jeffrey Shaver
  Jeffrey Shaver LinkedIn Profile  Jeffrey Shaver Twitter Account  Jeffrey Shaver News  Jeffrey Shaver on Facebook
VP - R & D
Timothy Henkel
  Timothy Henkel LinkedIn Profile  Timothy Henkel Twitter Account  Timothy Henkel News  Timothy Henkel on Facebook



Browse more venture capital transactions:

Prev: 11/26/2007: Carbylan Therapeutics venture capital transaction
Next: 11/26/2007: Vixxi Solutions venture capital transaction


Share this article


Where The Data Comes From

We do our best to report on every notable VC transaction. VC investment data records on this site are derived from news reports and company announcements. The data is sourced from, an affiliated venture.


Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities


Business Glossary